secwatch / observer
8-K filed April 15, 2026, 7:59 PM ET ticker ETON CIK 0001710340
debt confidence high sentiment positive materiality 0.50

Eton Pharmaceuticals amends credit facility: rate reduced, interest-only extended to Nov 2026

Eton Pharmaceuticals, Inc.

item 1.01item 2.03item 9.01

Machine-readable event card

schema_version
secwatch.filing_event.v1
accession
0001437749-26-012381
form_type
8-K
ticker
ETON
cik
0001710340
company_name
Eton Pharmaceuticals, Inc.
filed_at
2026-04-15T23:59:59+00:00
discovered_at
2026-05-14T18:02:32.785168+00:00
generated_at
2026-05-15T06:08:01.375398+00:00
sec_items
["1.01", "2.03", "9.01"]
event_type
debt
sentiment
positive
materiality_score
0.5
calibrated_materiality_score
0.5
confidence
high
secwatch_canonical_url
https://secwatch.observer/filing/0001437749-26-012381
json_url
https://secwatch.observer/filing/0001437749-26-012381.json
markdown_url
https://secwatch.observer/filing/0001437749-26-012381.md
text_url
https://secwatch.observer/filing/0001437749-26-012381.txt
edgar_index_url
https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/0001437749-26-012381-index.htm
edgar_primary_document_url
https://www.sec.gov/Archives/edgar/data/1710340/000143774926012381/eton20260409c_8k.htm
generated_by_model
deepseek-v4-flash:cloud@v2
review_status
machine_generated
human_reviewed
false
corrected
false
correction_note
null
correction_timestamp
null
superseded_by
null
JSON Markdown Plain text

Source-grounded claims

d4750439186bfd75c90b7aacae4571c865d95adb

Eton Pharmaceuticals, Inc. amended credit facility with SWK Funding LLC at SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0% maturing December 2027.

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

SEC 8-K Item 2.03/2.04 confidence 0.9 SEC evidence

4b088c2158f502487d169e9744e3688600a0fe2d

Eton Pharmaceuticals, Inc. amended SWK Credit Agreement with SWK Funding LLC (effective 2026-04-09).

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”).

SEC 8-K Item 1.01/1.02 confidence 0.9 SEC evidence

Comparable filings

TCPC

BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities

BlackRock TCP Capital Corp. June 1, 2026, 4:50 PM ET debt Items 1.01, 1.02, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

Item 1.01. Entry into a Material Definitive Agreement. On May 27, 2026 (the " Closing Date "), BlackRock TCP Capital Corp. (the " Company "), through its subsidiary, completed a $535,780,000 securitization of certain loans held by a subsidiary of the Company (the " CLO Transaction "). On the Closing Date and in connection with the CLO Transaction, BlackRock DLF 2026-C

Filing page SEC filing

EHC

Encompass Health issues $500M 5.875% notes due 2034; to redeem $400M of 4.500% notes due 2028

Encompass Health Corp June 1, 2026, 4:26 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

On May 29, 2026, Encompass Health Corporation (the “Company”) completed the issuance and sale of $500 million in aggregate principal amount of its 5.875% Senior Notes due 2034 (the “Notes”), along with the related guarantees of the Notes by certain of the Company’s subsidiaries (the “Guarantees”), in a private offering.

Filing page SEC filing

PGIM

PGIM Private Credit Fund enters $100M credit facility with $500M accordion option

PGIM Private Credit Fund May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

Repo Rate Average; and for Australian‐dollar advances, Bank Bill Swap Rate), in each case subject to a 0.25% floor. The initial facility amount of the Credit Facility is $100 million, with an accordion feature that permits increases, with the consent of the facility agent and the lenders, up to an aggregate commitment of $500 million. The Credit Facility has

Filing page SEC filing

LYV

Live Nation VenueCo closes €610M secured notes issuance backed by 4 venues

Live Nation Entertainment, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

On May 8, 2026, Live Nation VenueCo, LLC (“VenueCo”), a bankruptcy-remote, special purpose vehicle owned by certain bankruptcy-remote, special purpose entities (the “Participants”), which are indirect subsidiaries of Live Nation Entertainment, Inc. (the “Company”), closed its previously announced issuance of €610 million aggregate principal amount of fixed rate senior secured notes (the “Notes”).

Filing page SEC filing

HNOI

HNO International issues $67,500 convertible note and warrant to Monroe Street Capital

HNO International, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 2.03, 3.02, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

On May 5, 2026, HNO International, Inc. (the "Company") entered into a Securities Purchase Agreement (the "MSC Purchase Agreement") with Monroe Street Capital Partners, LP, a Delaware limited partnership (the "MSC Buyer"), pursuant to which the Company issued to the MSC Buyer a Convertible Promissory Note in the principal amount of $67,500

Filing page SEC filing

VIASP

Via Renewables enters $300M senior secured revolving credit facility, replaces prior agreement

Via Renewables, Inc. May 8, 2026, 7:59 PM ET debt Items 1.01, 1.02, 2.03, 3.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

In connection with entering into the Credit Agreement, the Company entered into an amended and restated subordinated promissory note (Note No. 9) (the “Subordinated Debt Facility”) with Spark HoldCo and Retailco, LLC (“Retailco”). The Subordinated Debt Facility allows the Company to draw advances in increments of no less than $1.0 million per advance up to $25.0 million through November 6, 2029.

Filing page SEC filing

JERSEY CENTRAL POWER & LIGHT CO

JCP&L issues $350M of 4.600% Senior Notes due 2030 for refinancing and capex

JERSEY CENTRAL POWER & LIGHT CO May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

On May 6, 2026 (the “Closing Date”), Jersey Central Power & Light Company (the “Company”) completed its offering of $350,000,000 aggregate principal amount of its 4.600% Senior Notes due 2030 (the “Notes”)

Filing page SEC filing

BKNG

Booking Holdings issues $750M of 5.375% Senior Notes due 2036

Booking Holdings Inc. May 7, 2026, 7:59 PM ET debt Items 1.01, 2.03, 8.01, 9.01

same fact type: debt_financing, material_agreement same SEC item: 1.01, 2.03, 9.01 same event type: debt similar materiality

This filing

On April 9, 2026, Eton Pharmaceuticals, Inc. (the “Company”) entered into a sixth amendment to its credit agreement (the “SWK Credit Agreement”), by and among the Company and SWK Funding LLC (“SWK”). Under the amended terms of the SWK Credit Agreement, the interest rate was reduced from a Secured Overnight Financing Rate (“SOFR”) plus 6.75% to SOFR plus 6.55% with the SOFR floor reduced to 2.75% from the previous 5.0%.

Comparable filing

in connection with the sale of $750,000,000 aggregate principal amount of the Company’s 5.375% Senior Notes due 2036

Filing page SEC filing

Source: SEC EDGAR
accession 0001437749-26-012381
view filing index on sec.gov
view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.